The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution

Randomized, double-blinded study of dacomitinib, an irreversible pan-human epidermal growth factor receptor (HER) inhibitor, versus erlotinib for second-line/third-line therapy of locally advanced/metastatic non-small cell lung cancer (ARCHER 1009).

Suresh S. Ramalingam

Consultant or Advisory Role - Boehringer Ingelheim; Genentech; Pfizer

Pasi A. Janne

Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Clovis; Genentech; Merrimack Pharmaceuticals ; Pfizer (U); Sanofi

Stock Ownership - GATEKEEPER Pharmaceuticals

Other Remuneration - LabCorp

Tony Mok

Consultant or Advisory Role - Amgen; AstraZeneca; AVEO; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis; Eisai; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Pfizer; Roche; Taiho Pharmaceutical

Honoraria - Amgen; AstraZeneca; AVEO; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis; Eisai; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Pfizer; Roche; Taiho Pharmaceutical

Research Funding - AstraZeneca

Kenneth O'Byrne

Consultant or Advisory Role - Pfizer; Roche

Honoraria - Pfizer; Roche

Research Funding - Genentech; Roche

Michael J. Boyer

Honoraria - Pfizer; Roche

Research Funding - Pfizer

Other Remuneration - Roche

Hui Zhang